Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SGN-30 in CD30+ Cutaneous Lymphoproliferative Disorders
NCT00099255Phase 2Completed
- Sponsor
- Seagen Inc.
- Start
- Sep 2004
- Primary completion
- Feb 2007
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of iratumumab in primary cutaneous anaplastic large cell lymphoma (PCALCL), lymphomatoid papulosis (LyP) and Mycosis fungoides with large cell transformation (MF-LCT), sponsored by Seagen Inc. Primary endpoints: Objective Response Rate, Duration of Response and 1 more. Started Sep 2004; status: completed.
02
Drugs
iratumumab
03
Conditions
primary cutaneous anaplastic large cell lymphoma (PCALCL)lymphomatoid papulosis (LyP)Mycosis fungoides with large cell transformation (MF-LCT)
Beyond the preview
Go deeper on NCT00099255.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00099255.